Apollo Hospitals Q3 profit rises 29 percent to Rs 86 crore on higher revenues

Published On 2019-02-12 03:45 GMT   |   Update On 2019-02-12 03:45 GMT

Apollo Hospitals on Saturday said that it plans to transfer the front-end retail pharmacy business carried out in the standalone pharmacy segment to a separate entity.


New Delhi: Apollo Hospitals Enterprise (AHEL) has posted 29 per cent growth in net profit to Rs 86.93 crore during the quarter ended December 31, 2018, compared to Rs 67.44 crore during the same quarter of the previous financial year.


Total income grew 16.8 per cent to Rs 2,046.75 crore during the quarter, as against Rs 1,864.13 crore during the corresponding quarter a year ago.


Sanjay Nayar, member and CEO of KKR India — an Independent Director of the company since 2014 — has resigned from the board with effect from February 9. The company, in a regulatory filing, said that Nayar has expressed his inability to devote adequate time to the affairs of the company going forward, given his increased professional commitments. Company officials were immediately not available for comment. Nayar was appointed to the post with effect from February 10, 2014, after the US-based Private Equity player Kohlberg Kravis Roberts (KKR) has infused around Rs 550 crore in AHEL’s holding company PCR Investments in October 2013, which was expected to be used to repay promoters' debt and build more hospitals.


The company on Saturday said that it plans to transfer the front-end retail pharmacy business carried out in the standalone pharmacy segment to a separate entity.


By way of a slump, the sale has not been reflected in the results since the receipt of necessary approvals is pending.


Also Read: Aurobindo Pharma Q3 profit rises 19.69 per cent to Rs 712 crore on robust sales
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News